Cure8 research brief
The findings suggest people with IBD on IV infliximab could switch to fixed-dose SC infliximab without losing drug exposure, and many may gain convenience and higher trough drug levels regardless of concomitant immunosuppressant use.
Adults with IBD receiving intravenous infliximab, patients considering switching to subcutaneous biologic formulations, clinicians who manage biologic dosing and monitoring, and researchers studying biologic delivery methods.
This single-centre prospective study followed 35 adults with IBD who were in clinical remission on IV infliximab and switched to biweekly SC infliximab for 24 weeks. The primary outcome—area under the concentration–time curve (AUC)—was comparable between IV and SC dosing.
Trough infliximab concentrations were higher after switching to SC dosing, and this increase persisted at ≥12 months across patients on monotherapy, combination therapy, or after stopping immunosuppressants.
Patients reported a substantial decrease in time burden (median reduction ~9.3 hours per 6 months) and a small improvement in IBD-specific quality of life (IBDQ-NL). Nearly all participants (97%) remained on SC infliximab at 24 weeks, and no disease exacerbations were reported during follow-up.
The study addresses a practical question for people receiving infliximab: SC dosing may keep exposure at least equivalent while raising trough levels and reducing infusion-related time demands.
This report is a single-centre prospective pharmacokinetic study with 35 patients and an abstract-level source. The structured content is grounded in the article abstract; it does not replace individualized medical advice. Details on clinical efficacy beyond remission maintenance, long-term safety, and broader generalizability may require larger multicentre studies.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
This large pediatric registry study suggests children starting infliximab biosimilars have similar 12‑month clinical outcomes and treatment durability as those starting the originator drug — reassuring for patients and...
Label updates for AVSOLA affect people with Crohn’s disease and ulcerative colitis because they summarize approved uses, dosing, and important safety warnings (infection, TB, hepatitis B, and lymphoma risk) that guide...
